Overall Survival of Patients with Metastatic Renal Cell Carcinoma Following the Introduction of Targeted and Immunotherapies: A Norwegian Retrospective, Real-World Registry Data Study (RECON3)
Katarina Puco,1 Cathrine S Notland,2 Robert Szulkin,3,4 Christian Jonasson,5 Christian Beisland,6,7 Tom B Johannesen,8 Oddvar Solli,9 Jan Oldenburg,10,11 Daniel Heinrich12 1Department of Oncology, Hematology and Palliative Care, Lovisenberg Diaconal Hospital, Oslo, Norway; 2Department of Medical Aff...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-01-01
|
| Series: | Cancer Management and Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/overall-survival-of-patients-with-metastatic-renal-cell-carcinoma-foll-peer-reviewed-fulltext-article-CMAR |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832590422819471360 |
|---|---|
| author | Puco K Notland CS Szulkin R Jonasson C Beisland C Johannesen TB Solli O Oldenburg J Heinrich D |
| author_facet | Puco K Notland CS Szulkin R Jonasson C Beisland C Johannesen TB Solli O Oldenburg J Heinrich D |
| author_sort | Puco K |
| collection | DOAJ |
| description | Katarina Puco,1 Cathrine S Notland,2 Robert Szulkin,3,4 Christian Jonasson,5 Christian Beisland,6,7 Tom B Johannesen,8 Oddvar Solli,9 Jan Oldenburg,10,11 Daniel Heinrich12 1Department of Oncology, Hematology and Palliative Care, Lovisenberg Diaconal Hospital, Oslo, Norway; 2Department of Medical Affairs, Pfizer AS, Oslo, Norway; 3SDS Life Science, Stockholm, Sweden; 4Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Solna, Sweden; 5Department of Public Health and Nursing, Faculty of Medicine and Health Science, Norwegian University of Science and Technology (NTNU), Trondheim, Norway; 6Department of Urology, Haukeland University Hospital, Bergen, Norway; 7Department of Clinical Medicine, University of Bergen, Bergen, Norway; 8Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway; 9Health and Value, Pfizer AS, Oslo, Norway; 10Department of Oncology, Akershus University Hospital HF, Lørenskog, Norway; 11Faculty of Medicine, University of Oslo, Oslo, Norway; 12Department of Radiotherapy and Oncology, Innlandet Hospital Trust HF, Division Gjøvik/Lillehammer, NorwayCorrespondence: Katarina Puco, Department of Oncology, Hematology and Palliative Care, Lovisenberg Diaconal Hospital, Oslo, Norway, Tel +47 416 86 298, Email katarina.puco@lds.noPurpose: In Norway, 5-year survival rates of patients with renal cell carcinoma (RCC) are increasing. The objective of this study was to describe the survival of real-world patients with metastatic RCC (mRCC) across Norway and to identify associated factors. The results may provide additional information on the benefits of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) in clinical practice.Patients and Methods: We performed a longitudinal, retrospective, non-interventional cohort study using data from four national registries. The study included adults diagnosed with mRCC between 1 January 1995 and 31 December 2018. Primary endpoint was to evaluate overall survival (OS) in all included patients. Secondary endpoints included further analysis of treatment patterns and possible impact on OS. Secondary endpoint analysis was performed in patients diagnosed with mRCC between 1 January 2008 and 31 December 2018, as complete data on systemic therapies were available from 2008 and onwards.Results: In total, 4078 patients were diagnosed with mRCC in the period from 1995 to 2018. The median OS since initial mRCC diagnosis was 1.17 years. OS appeared to improve over time, 5-year OS was 10% in patients diagnosed in the period 1995– 2001 compared to 25% in 2012– 2015. The secondary analysis included 2338 patients. Fifty-five percent (55%) of the patients received systemic treatment. No differences were observed in the number of treatment lines administered over time or in the number of lines of treatment administered according to tumor histology. Among 343 patients who received ≥ 3 treatment lines, we observed longer OS in patients who received an ICI as a part of their treatment, with a median OS of 4.51 compared to 2.31 years.Conclusion: Provision of information into registries is mandatory in Norway. This retrospective, registry-based study provides real-world evidence on patient outcomes and treatments of the Norwegian patients with mRCC in the period from 1995 to 2018.Keywords: real-world data, immunotherapy, molecular targeted therapy, Norway, renal cell carcinoma |
| format | Article |
| id | doaj-art-c226ed749ea8463298bd64d9f046ff2c |
| institution | Kabale University |
| issn | 1179-1322 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Cancer Management and Research |
| spelling | doaj-art-c226ed749ea8463298bd64d9f046ff2c2025-01-23T18:50:32ZengDove Medical PressCancer Management and Research1179-13222025-01-01Volume 1710311299480Overall Survival of Patients with Metastatic Renal Cell Carcinoma Following the Introduction of Targeted and Immunotherapies: A Norwegian Retrospective, Real-World Registry Data Study (RECON3)Puco KNotland CSSzulkin RJonasson CBeisland CJohannesen TBSolli OOldenburg JHeinrich DKatarina Puco,1 Cathrine S Notland,2 Robert Szulkin,3,4 Christian Jonasson,5 Christian Beisland,6,7 Tom B Johannesen,8 Oddvar Solli,9 Jan Oldenburg,10,11 Daniel Heinrich12 1Department of Oncology, Hematology and Palliative Care, Lovisenberg Diaconal Hospital, Oslo, Norway; 2Department of Medical Affairs, Pfizer AS, Oslo, Norway; 3SDS Life Science, Stockholm, Sweden; 4Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Solna, Sweden; 5Department of Public Health and Nursing, Faculty of Medicine and Health Science, Norwegian University of Science and Technology (NTNU), Trondheim, Norway; 6Department of Urology, Haukeland University Hospital, Bergen, Norway; 7Department of Clinical Medicine, University of Bergen, Bergen, Norway; 8Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway; 9Health and Value, Pfizer AS, Oslo, Norway; 10Department of Oncology, Akershus University Hospital HF, Lørenskog, Norway; 11Faculty of Medicine, University of Oslo, Oslo, Norway; 12Department of Radiotherapy and Oncology, Innlandet Hospital Trust HF, Division Gjøvik/Lillehammer, NorwayCorrespondence: Katarina Puco, Department of Oncology, Hematology and Palliative Care, Lovisenberg Diaconal Hospital, Oslo, Norway, Tel +47 416 86 298, Email katarina.puco@lds.noPurpose: In Norway, 5-year survival rates of patients with renal cell carcinoma (RCC) are increasing. The objective of this study was to describe the survival of real-world patients with metastatic RCC (mRCC) across Norway and to identify associated factors. The results may provide additional information on the benefits of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) in clinical practice.Patients and Methods: We performed a longitudinal, retrospective, non-interventional cohort study using data from four national registries. The study included adults diagnosed with mRCC between 1 January 1995 and 31 December 2018. Primary endpoint was to evaluate overall survival (OS) in all included patients. Secondary endpoints included further analysis of treatment patterns and possible impact on OS. Secondary endpoint analysis was performed in patients diagnosed with mRCC between 1 January 2008 and 31 December 2018, as complete data on systemic therapies were available from 2008 and onwards.Results: In total, 4078 patients were diagnosed with mRCC in the period from 1995 to 2018. The median OS since initial mRCC diagnosis was 1.17 years. OS appeared to improve over time, 5-year OS was 10% in patients diagnosed in the period 1995– 2001 compared to 25% in 2012– 2015. The secondary analysis included 2338 patients. Fifty-five percent (55%) of the patients received systemic treatment. No differences were observed in the number of treatment lines administered over time or in the number of lines of treatment administered according to tumor histology. Among 343 patients who received ≥ 3 treatment lines, we observed longer OS in patients who received an ICI as a part of their treatment, with a median OS of 4.51 compared to 2.31 years.Conclusion: Provision of information into registries is mandatory in Norway. This retrospective, registry-based study provides real-world evidence on patient outcomes and treatments of the Norwegian patients with mRCC in the period from 1995 to 2018.Keywords: real-world data, immunotherapy, molecular targeted therapy, Norway, renal cell carcinomahttps://www.dovepress.com/overall-survival-of-patients-with-metastatic-renal-cell-carcinoma-foll-peer-reviewed-fulltext-article-CMARreal-world dataimmunotherapymolecular targeted therapynorwayrenal cell carcinoma. |
| spellingShingle | Puco K Notland CS Szulkin R Jonasson C Beisland C Johannesen TB Solli O Oldenburg J Heinrich D Overall Survival of Patients with Metastatic Renal Cell Carcinoma Following the Introduction of Targeted and Immunotherapies: A Norwegian Retrospective, Real-World Registry Data Study (RECON3) Cancer Management and Research real-world data immunotherapy molecular targeted therapy norway renal cell carcinoma. |
| title | Overall Survival of Patients with Metastatic Renal Cell Carcinoma Following the Introduction of Targeted and Immunotherapies: A Norwegian Retrospective, Real-World Registry Data Study (RECON3) |
| title_full | Overall Survival of Patients with Metastatic Renal Cell Carcinoma Following the Introduction of Targeted and Immunotherapies: A Norwegian Retrospective, Real-World Registry Data Study (RECON3) |
| title_fullStr | Overall Survival of Patients with Metastatic Renal Cell Carcinoma Following the Introduction of Targeted and Immunotherapies: A Norwegian Retrospective, Real-World Registry Data Study (RECON3) |
| title_full_unstemmed | Overall Survival of Patients with Metastatic Renal Cell Carcinoma Following the Introduction of Targeted and Immunotherapies: A Norwegian Retrospective, Real-World Registry Data Study (RECON3) |
| title_short | Overall Survival of Patients with Metastatic Renal Cell Carcinoma Following the Introduction of Targeted and Immunotherapies: A Norwegian Retrospective, Real-World Registry Data Study (RECON3) |
| title_sort | overall survival of patients with metastatic renal cell carcinoma following the introduction of targeted and immunotherapies a norwegian retrospective real world registry data study recon3 |
| topic | real-world data immunotherapy molecular targeted therapy norway renal cell carcinoma. |
| url | https://www.dovepress.com/overall-survival-of-patients-with-metastatic-renal-cell-carcinoma-foll-peer-reviewed-fulltext-article-CMAR |
| work_keys_str_mv | AT pucok overallsurvivalofpatientswithmetastaticrenalcellcarcinomafollowingtheintroductionoftargetedandimmunotherapiesanorwegianretrospectiverealworldregistrydatastudyrecon3 AT notlandcs overallsurvivalofpatientswithmetastaticrenalcellcarcinomafollowingtheintroductionoftargetedandimmunotherapiesanorwegianretrospectiverealworldregistrydatastudyrecon3 AT szulkinr overallsurvivalofpatientswithmetastaticrenalcellcarcinomafollowingtheintroductionoftargetedandimmunotherapiesanorwegianretrospectiverealworldregistrydatastudyrecon3 AT jonassonc overallsurvivalofpatientswithmetastaticrenalcellcarcinomafollowingtheintroductionoftargetedandimmunotherapiesanorwegianretrospectiverealworldregistrydatastudyrecon3 AT beislandc overallsurvivalofpatientswithmetastaticrenalcellcarcinomafollowingtheintroductionoftargetedandimmunotherapiesanorwegianretrospectiverealworldregistrydatastudyrecon3 AT johannesentb overallsurvivalofpatientswithmetastaticrenalcellcarcinomafollowingtheintroductionoftargetedandimmunotherapiesanorwegianretrospectiverealworldregistrydatastudyrecon3 AT sollio overallsurvivalofpatientswithmetastaticrenalcellcarcinomafollowingtheintroductionoftargetedandimmunotherapiesanorwegianretrospectiverealworldregistrydatastudyrecon3 AT oldenburgj overallsurvivalofpatientswithmetastaticrenalcellcarcinomafollowingtheintroductionoftargetedandimmunotherapiesanorwegianretrospectiverealworldregistrydatastudyrecon3 AT heinrichd overallsurvivalofpatientswithmetastaticrenalcellcarcinomafollowingtheintroductionoftargetedandimmunotherapiesanorwegianretrospectiverealworldregistrydatastudyrecon3 |